department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Latisse · pharmadog

pharmadog
drugs
Latisse

drug

patient view →

Lumigan

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

all catalysts(1)

approval · 1

BIMATOPROST — FDA approval

News(0)

no news has mentioned this drug yet

brand

Latisse

generic

bimatoprost

MOA

Prostanoid FP receptor agonist

indication

Ocular Hypertension

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 19, 2026

165 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Jun 8, 2036formulationUS 10314780
Oct 31, 2034formulationUS 9492316
Oct 31, 2034method-of-use (U-2759)US 9980974
Jul 15, 2031compositionUS 8629185
Apr 24, 2029formulationUS 77993362.8y
Jun 13, 2027compositionUS 7851504341d
Apr 7, 2027method-of-use (U-2759)US 8206737274d
Dec 19, 2026formulationUS 10441543165d
Dec 19, 2026formulationUS 9149428165d

FDA exclusivities (1)

Sep 9, 2028NDFNew Dosage Form (3y)2.2y

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$AMRX16.92-1.34%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 5

drugBIMATOPROST3 co-mentions · 3 sources
drugbimatoprost CR3 co-mentions · 3 sources
drugbimatoprost SR3 co-mentions · 3 sources
tagApproval2 co-mentions · 1 sources
tagRecall2 co-mentions · 2 sources

Trials studying Lumigan

phase2AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertensionrecruitingn=96
phase4Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Userecruitingn=20
phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)recruitingn=400
phase3Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)recruitingn=400
N/AEvaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucomacompletedn=24
phase3Long-term Safety and Efficacy Extension Trial of Bimatoprost SRactive not recruitingn=455
phase2Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solutionactive not recruitingn=201
phase3Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertensioncompletedn=515

more trials →